(SGRY) Surgery Partners, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SGRY) Surgery Partners, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Surgery Partners, Inc. BCG Matrix helps you assess how the company’s business units or services fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
108 ambulatory surgery centers
Surgery Partners, Inc.'s 108 ambulatory surgery centers are the core growth platform in a 126-facility network across 31 states. Same-day surgery keeps shifting outpatient, so demand stays structurally strong. This makes the ASC base a clear Star in the BCG matrix, with scale and operating leverage still expanding.
Orthopedics and musculoskeletal surgery
Orthopedics and musculoskeletal surgery is a Star for Surgery Partners, Inc. because joint and spine cases keep shifting to outpatient care; CMS has expanded the ASC-approved procedure list to more than 500 codes. This is one of the fastest-growing ambulatory lines, with total joint replacements already common in ASCs. Surgery Partners, Inc. can scale it by tying in surgeons and packing more cases into dense centers.
Gastroenterology and endoscopy
Gastroenterology and endoscopy is a Star for Surgery Partners, Inc. because GI care is high-volume and keeps moving out of hospitals; outpatient endoscopy already handles most routine cases, supporting steady ASC utilization. In 2024, Surgery Partners generated $3.1 billion in revenue, and this service line fits its low-cost, repeat-case model. That mix supports recurring flow and strong scheduling density.
Anesthesia services
Anesthesia services is a Star because it scales with Surgery Partners, Inc.'s surgical case volume and ASC buildout. In 2025, outpatient procedures kept rising, so demand stayed high across both owned centers and affiliated providers. This makes the line a strong cash driver with limited demand risk.
It also benefits from Surgery Partners, Inc.'s broad network of 200+ facilities, since each added case can pull anesthesia revenue higher. The service is tightly linked to same-day surgery, so more orthopedic, GI, and pain cases mean more utilization.
- Volume-linked, high-repeat demand
- Supports owned and affiliated sites
- Rises with outpatient case growth
De novo ASC development
De novo ASC development is a Star for Surgery Partners, Inc. because each new center can create share in local surgical markets that are still growing. It is also one of the clearest ways capital can turn into long-run scale, since a ramped center adds surgeons, cases, and payer mix over time.
- New centers seed future market share.
- Capital spend can compound into scale.
- Ramp speed drives the return.
Surgery Partners’ ASC Network Powers Same-Day Care Growth
Surgery Partners, Inc.'s Star assets are its 108 ASCs in a 126-facility, 31-state network, plus orthopedics, GI, anesthesia, and de novo development. These lines ride the shift to same-day care, which lifted 2024 revenue to $3.1 billion and kept utilization high in 2025.
| Star area | Latest data | Why it fits |
|---|---|---|
| ASCs | 108 centers | Outpatient volume growth |
| Network | 126 facilities, 31 states | Scale and density |
| Revenue | $3.1 billion, 2024 | High case flow |
What is included in the product
Detailed Word Document
Surgery Partners’ BCG Matrix maps its service lines into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
One-page Surgery Partners, Inc. BCG Matrix that quickly spots winners and laggards to simplify strategy decisions
Reference Sources
Provides a credible source trail for Surgery Partners, Inc. so teams can verify assumptions quickly and make better decisions.
Cash Cows
18 surgical hospitals
Surgery Partners, Inc. reported 18 dedicated surgical hospitals, a mature asset base that usually throws off steadier cash flow than newer ASCs. These hospitals also help lock in referral patterns in local markets, which supports case volume and pricing power. As a cash cow in the BCG matrix, this segment can fund growth elsewhere while carrying lower ramp-up risk.
General surgery
General surgery is a cash cow for Surgery Partners, Inc. because it is repeatable, high-volume care that keeps operating rooms busy with little service-line reinvention. In 2025, Surgery Partners reported about $3.1 billion in revenue, and that scale is helped by steady, everyday procedures across many markets. This kind of mix fills capacity and supports cash flow.
Ophthalmology
Ophthalmology is a clear Cash Cow for Surgery Partners, Inc. because cataract and other eye cases are highly standardized, quick to turn, and recur at scale; U.S. cataract surgery tops 4 million procedures a year. That steady volume supports strong operating leverage and dependable cash generation, even if growth is modest.
Pain management
Pain management fits Cash Cows because it is a mature outpatient line with steady demand and lower volatility than newer growth areas. For Surgery Partners, Inc., this kind of procedure mix can support repeat cash flow with relatively modest capital needs, since many cases are short-stay and do not need heavy site build-out. The U.S. outpatient shift stays strong, with ambulatory surgery centers still taking share from higher-cost hospital settings.
- Stable, repeat procedure demand
- Lower reinvestment than growth lines
- Cash flow often stays consistent
- Less exposed to fast category swings
Embedded ancillary services
Embedded ancillary services at Surgery Partners, Inc.—imaging, pharmacy, lab, physical therapy, and wound care—act like cash cows because they sit inside the existing outpatient site base, so they need little new build-out. In 2025, the model still scales off a large network of 200+ facilities, which keeps utilization high and capex light.
- Steady demand from same-site patients
- Low growth spend, strong cash conversion
- Higher value per surgical episode
Surgery Partners’ Cash Cows: 18 Hospitals Power Steady Cash Flow
Cash Cows at Surgery Partners, Inc. are the mature lines that keep cash flowing: 18 dedicated surgical hospitals, general surgery, ophthalmology, pain management, and embedded ancillaries. In 2025, Surgery Partners, Inc. generated about $3.1 billion in revenue, supported by repeat, high-volume outpatient care. These units need less reinvestment than growth bets and help fund expansion.
| Cash Cow | Key data |
|---|---|
| Hospitals | 18 sites |
| Revenue | ~$3.1B in 2025 |
| Network | 200+ facilities |
What You See Is What You Get
Surgery Partners, Inc. Reference Sources
You’re previewing the exact Surgery Partners, Inc. BCG Matrix document you’ll receive after purchase. The full file is identical to this preview—no hidden sections, no demo content, and no watermarks. It’s ready for immediate use in strategy reviews, presentations, or internal analysis.
Dogs
Obstetrics ancillary care
Obstetrics ancillary care is a Dog for Surgery Partners, Inc. because it is not a core ASC growth engine and needs more labor, room time, and on-call coverage than same-day surgery. It also scales poorly inside an outpatient platform, since obstetrics depends on 24/7 staffing and higher clinical complexity, not high-turnover procedures. That makes it less attractive than core ASCs, which drove Surgery Partners, Inc. to report 140 facilities and about 50,000 procedures per month in 2025.
Oncology ancillary care
Oncology ancillary care is a weak fit for Surgery Partners, Inc.'s outpatient model. It needs deeper clinical infrastructure, multidisciplinary teams, and scale, while most revenue stays tied to complex care pathways, not fast-turn surgery volumes. That makes it a low-share BCG "Dog" with limited near-term upside.
Wound care services
Wound care services fit Dogs in Surgery Partners, Inc.'s BCG Matrix because demand is real but local, with low scale and modest incremental return. In 2025, wound care remained a small, site-based specialty, while Surgery Partners still leaned on larger, repeatable outpatient volumes in orthopedics and GI.
The service line usually depends on referral density and clinic-level staffing, so growth is slower than higher-throughput procedures. That makes it useful, but not a major capital priority.
For Surgery Partners, Inc., the economics point to hold, not heavy expansion: limited scale, narrower margins, and weaker network effects than core surgical lines.
Small non-core physician practices
Small non-core physician practices fit the Dogs bucket because minority stakes below 50% are hard to defend in fragmented local markets, and they can absorb integration spend without enough revenue lift in 2025. For Surgery Partners, Inc., these assets can also pull management away from larger ASC opportunities that drive more value.
- Minority control weakens pricing power.
- Integration costs can outrun returns.
- Management time gets tied up fast.
Low-density rural sites
Low-density rural sites are a Dog for Surgery Partners, Inc. because thin-population markets cap procedure volume, so fixed costs are spread over fewer cases. That keeps margins under pressure and makes it harder to build durable share leadership versus denser metro markets. In FY2025, the company still depended on scale in higher-volume sites to lift EBITDA, which shows why sparse markets stay weak contributors.
- Low volume limits case growth.
- Fixed costs weigh on margins.
- Share gains are harder to win.
Low-Volume Dogs Still Weigh on Surgery Partners
In 2025, Obstetrics ancillary care, oncology ancillary care, wound care, small non-core physician practices, and low-density rural sites stayed Dogs for Surgery Partners, Inc. because they had weaker scale, lower margins, and poorer fit than high-volume ASCs. Surgery Partners, Inc. operated 140 facilities and about 50,000 procedures per month in 2025, so capital still favored dense outpatient volumes. These lines are best held, trimmed, or left to run off.
| Dog | 2025 signal | Why weak |
|---|---|---|
| Obstetrics | 24/7 staffing | Low ASC fit |
| Rural sites | Thin volume | Fixed costs bite |
Question Marks
Urgent care facilities
Urgent care is a fast-growing but crowded market, with about 14,000 U.S. centers and more than 200 million visits a year. Surgery Partners, Inc. only has indirect exposure through ancillary services, so this is not a core leadership area for the business. To win share, it would need fresh capital, marketing, and tighter site expansion.
Outpatient total joint replacements
Outpatient total joint replacements are a high-growth question mark for Surgery Partners, Inc.; CMS added total knee arthroplasty to the ASC list in 2020 and total hip arthroplasty in 2021, which keeps more cases moving out of hospitals. If Surgery Partners, Inc. keeps winning surgeons and payer contracts, this can turn from a small base into a future star.
Robotics-assisted surgery
Robotics-assisted surgery is a Question Mark for Surgery Partners, Inc. because it can draw surgeons and patients, but share is still being built in a market led by a few large platforms. New systems often cost about $1.5 million to $2.5 million, plus training and service spend, so adoption needs volume to pay off.
The category is growing, but the economic hurdle stays high. If Surgery Partners, Inc. converts more cases to robotic care, it can raise mix and referrals, yet it must prove it can win share without dragging margins.
New-state expansion
New-state expansion is a Question Mark for Surgery Partners, Inc.: it can drive growth, but each entry starts with low local share and a long ramp. The Company’s 31-state footprint shows the model can travel, yet every new market still needs capital, surgeons, and referral ties before it can scale. One clean fact: expansion is a launch point, not a moat.
- 31-state footprint supports market entry
- Low share at launch keeps returns uncertain
- New sites need capital and physicians
- Referrals decide early market traction
Value-based care partnerships
Value-based care partnerships look like a question mark for Surgery Partners, Inc.: the model can grow as payers and surgeons push lower-cost settings, but market share is still early. Success hinges on tight contracting, better outcomes, and enough scale to spread fixed costs; Surgery Partners, Inc. reported $3.1 billion in 2024 revenue, showing room to convert volume into bundled and risk-based deals.
- Early share, but strong growth runway.
- Best if outcomes beat hospital costs.
- Scale and contracts decide the winner.
Surgery Partners’ Growth Bets: High Upside, Still Proving Scale
Question Marks in Surgery Partners, Inc. are growth bets with low share today: urgent care, robotics, new-state entry, and value-based care. The upside is real, but each needs capital, surgeon pull, and payer wins. Surgery Partners, Inc. posted $3.1 billion revenue in 2024, yet these areas still need proof of scale.
| Area | Signal |
|---|---|
| Robotics | $1.5M-$2.5M per system |
| Total joints | CMS-approved ASC growth |
| New states | 31-state footprint, low local share |
| Value-based care | Early share, scale needed |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.